Recruiting Acute Myeloid Leukemia Studies in Tucson
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia...
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (I...
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day contin...
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with...
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patien...
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit...
About Acute Myeloid Leukemia Clinical Trials in Tucson
Acute myeloid leukemia (AML) is a fast-growing cancer of the blood and bone marrow characterized by abnormal myeloid cells. It is the most common acute leukemia in adults. Treatment typically includes intensive chemotherapy and may involve stem cell transplant.
There are currently 6 acute myeloid leukemia clinical trials recruiting participants in Tucson, ARIZONA. These studies are seeking a combined 2,971 participants. Research is being sponsored by Children's Oncology Group, Daiichi Sankyo, Delta-Fly Pharma, Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Acute Myeloid Leukemia Clinical Trials in Tucson — FAQ
Are there acute myeloid leukemia clinical trials in Tucson?
Yes, there are 6 acute myeloid leukemia clinical trials currently recruiting in Tucson, ARIZONA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Tucson?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.
Are clinical trials in Tucson free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.
What acute myeloid leukemia treatments are being tested?
The 6 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for acute myeloid leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov